(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
4 days till quarter result
(bmo 2024-05-08)
Expected move: +/- 12.54%
4.14% $ 1.510
@ $10.08
Wydano: 14 vas. 2024 @ 16:30
Zwrot: -85.02%
Poprzedni sygnał: vas. 13 - 16:30
Poprzedni sygnał:
Zwrot: 3.70 %
Live Chart Being Loaded With Signals
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders...
Stats | |
---|---|
Dzisiejszy wolumen | 1.60M |
Średni wolumen | 1.84M |
Kapitalizacja rynkowa | 82.51M |
EPS | $0 ( 2024-03-05 ) |
Następna data zysków | ( $-0.680 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.570 |
ATR14 | $0.00800 (0.53%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-27 | Braunstein Scott | Buy | 50 000 | Common Stock |
2024-03-27 | Braunstein Scott | Sell | 50 000 | Stock Option (Right to Buy) |
2024-02-20 | Shafer Christina | Sell | 2 153 | Common Stock |
2024-02-20 | Manning Martha E | Sell | 1 894 | Common Stock |
2024-02-16 | Hulihan Joseph | Sell | 2 814 | Common Stock |
INSIDER POWER |
---|
87.63 |
Last 96 transactions |
Buy: 2 669 285 | Sell: 293 774 |
Wolumen Korelacja
Marinus Pharmaceuticals Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
ACOR | 0.952 |
YVR | 0.939 |
ZD | 0.913 |
ENNVU | 0.909 |
DUNE | 0.908 |
ARIZ | 0.906 |
ARVL | 0.906 |
CIIG | 0.902 |
MBIO | 0.901 |
POAI | 0.894 |
10 Najbardziej negatywne korelacje | |
---|---|
GRIN | -0.943 |
PPTA | -0.93 |
GALT | -0.928 |
CATB | -0.926 |
CSTE | -0.921 |
ABIO | -0.921 |
AURC | -0.921 |
GAIA | -0.903 |
CADL | -0.901 |
NYMX | -0.9 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Marinus Pharmaceuticals Korelacja - Waluta/Towar
Marinus Pharmaceuticals Finanse
Annual | 2023 |
Przychody: | $30.99M |
Zysk brutto: | $28.50M (91.98 %) |
EPS: | $-2.63 |
FY | 2023 |
Przychody: | $30.99M |
Zysk brutto: | $28.50M (91.98 %) |
EPS: | $-2.63 |
FY | 2022 |
Przychody: | $25.48M |
Zysk brutto: | $25.14M (98.67 %) |
EPS: | $-0.510 |
FY | 2021 |
Przychody: | $15.35M |
Zysk brutto: | $13.87M (90.37 %) |
EPS: | $-2.69 |
Financial Reports:
No articles found.
Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej